{"id": "chatcmpl-8JZnAUW7gkjrDTrOHvmZdfZQFNeYt", "object": "chat.completion", "created": 1699676508, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. Maintenance monotherapy with olaparib significantly prolongs progression-free survival in patients with platinum-sensitive relapsed serous ovarian cancer.\n2. The benefit of olaparib is greater in patients with a BRCA1/2 mutation (BRCAm).\n3. Olaparib is a poly(ADP-ribose) polymerase inhibitor.\n4. The comparison is made against a placebo.\n5. The patients in the study have platinum-sensitive relapsed serous ovarian cancer.\n6. Some patients in the study have a BRCA1/2 mutation."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 87, "completion_tokens": 117, "total_tokens": 204}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: Maintenance monotherapy with the poly(ADP-ribose) polymerase inhibitor olaparib significantly prolongs progression-free survival over placebo in patients with platinum-sensitive relapsed serous ovarian cancer, with greatest benefit seen in patients with a BRCA1/2 mutation (BRCAm).\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}